Uterine transplant for women with infertility due to absence of uterus
Official title: Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Factor Infertility
Run by Baylor College of Medicine · NCT05263076 · Data updated 2026-11-12
This study is testing if a uterine transplant from a donor can help women with no uterus due to infertility become pregnant and have a baby.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years to 65 Years |
| Sex | Women only |
| Enrollment | 10 (estimated) |
| Sponsor | Baylor College of Medicine Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | June 3, 2022 |
| Main results expected | December 2030 |
| Study ends | December 2030 |
| Registry record updated | April 29, 2026 |
| Trial ID | NCT05263076 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women aged 20-40 diagnosed with Absolute Uterine Factor Infertility who have at least one functioning ovary.
✕Probably not a fit
Patients with active infections or those who do not meet the eligibility criteria, such as having no functioning ovaries, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to treat Absolute Uterine Factor Infertility (AUFI) through uterine transplantation using a uterus from either a living or deceased donor. It will involve 10 biologically female participants aged 20-40 who have at least one functioning ovary. The study will assess the physical, emotional, and mental readiness of candidates through consultations and various procedures before proceeding with the transplant. The ultimate goal is to achieve pregnancy and live birth following the transplantation.
Why it matters
Potential benefit: If successful, this procedure could provide a viable option for women with AUFI to conceive and carry their own children.
How similar studies have gone: Previous studies on uterine transplants have shown success, with live births reported following similar procedures, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
RECIPIENT INCLUSION CRITERIA 1. Women who are diagnosed with Absolute Uterine Factor Infertility (AUFI) and who have at least one functioning ovary. 2. Women of childbearing age (20-40 years old) who are biologically female (XX karyotype). 3. Subjects will not have active human 142 papillomavirus (HPV) or active cervical dysplasia present. 4. Subjects will have negative testing for Gonorrhea Chlamydia and Syphilis and will not have any active bacterial vaginosis or candida infection. (Subjects with previously treated STDs will be included if the infection is no longer present and has no impact. If a subject develops an STD/infection pre-operatively, she will be treated and monitored for a period of 3 months until she is no longer affected. She will then become eligible for transplant. If a subject develops an STD/infection after transplant/during pregnancy she will be treated appropriately. Prior to the embryo transfer the patient will be tested and treated if necessary. Any patient with an active STD/infection will be ineligible for any elective procedure until she is tested and treated appropriately.) 5. Subjects who are HSV-2 negative or who have a history of HSV-2 with no current symptoms. Subjects may require preventative maintenance per study doctor discretion. 6. Subjects have received counseling regarding all fertility options and alternatives to uterine transplant such as adoption or surrogate pregnancy. 7. Subjects are willing to undergo in-vitro fertilization to obtain the necessary 4 viable embryos required for eligibility for transplant if they have not already banked 4 viable embryos. 8. Subjects have been evaluated by a fertility specialist and determined to have good ovarian reserve and reproductive potential. 9. Subjects must agree that in the event of withdrawal from the study while the transplanted uterus is in place, unless she is enrolled in an equivalent uterine transplant program, she will be required to undergo a hysterectomy for her own safety. 10. Subject meets psychological recipient criteria. 11. Subject must be willing to complete questionnaires about their infant's growth and development and return them to the study team. RECIPIENT EXCLUSION CRITERIA 1. Subject with Diabetes Mellitus Type I and II by medical history or elevated hemoglobin A1c blood test. 2. Subject has known hypersensitivity to Tacrolimus, Thymoglobulin or Everolimus. 3. Subject with a diagnosis of hypertension, or any other significant medical condition that makes this procedure unsafe or is a contraindication to surgery or anesthesia. 4. Subject who has a history of solid organ or bone marrow transplant, per investigator's discretion. 5. Subject who has a history of cancer, per investigator's discretion. 6. Subject with a body mass index \>30. 7. Subject with an active infection including candida and/or bacterial vaginosis. 8. Subject who is seropositive for HIV, HBV, HCV. 9. Subject with technical obstacles as per anatomical malformations, which pose a high surgical risk in the judgment of the investigator. 10. Subject unwilling or unable to comply with study requirements. 11. Subject unable to undergo in-vitro fertilization or not cleared for transplant. 12. Subject who has smoked within the last 6 months. 13. Subject who has alcohol or drug abuse within 12 months of screening. 14. Subject with any pre-existing clinical or medical conditions that would put the subject at an increased risk. Of note, for Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome, the investigators will favor Type 1 variants as Type 2 is associated with skeletal/spinal and renal anomalies, making them higher risk candidates. DONOR INCLUSION CRITERIA 1. Women must be between 25-65 years of age. If a subject is less than 40 years old she must be certain that she does not wish to carry more children, and she will attest to this decision. 2. Subjects will not have active human 142 papillomavirus (HPV) or active cervical dysplasia present. 3. Subjects will have negative testing for Gonorrhea, Chlamydia and Syphilis and will not have any active bacterial vaginosis or candida infection. (Subjects with previously treated STDs will be included if the infection is no longer present and has no impact. If a subject develops an STD/infection pre-operatively, she will be treated and monitored for a period of 3 months until she is no longer affected. Any patient with an active STD/infection will be ineligible for any elective procedure until she is tested and treated appropriately.) 4. Subjects who are HSV-2 negative, or have a history of HSV-2 but with no current symptoms. Subjects may require preventative maintenance per study doctor discretion. 5. Subjects will have a normal uterus on sonogram and CT. 6. Subjects will have normal psychological donor criteria (if living). 7. Subjects will have had at least one prior full term live birth. DONOR EXCLUSION CRITERIA 1. Donor over the age of 65. 2. Body mass index \>30. 3. Subject with an active infection including candida and/or bacterial vaginosis. 4. Subject who is seropositive for HIV, HBV, HCV 5. Subject who has had cancer in the last five years. 6. Subject with any pre-existing clinical or medical condition that would place the subject at an increased risk or would be a contraindication to surgery or anesthesia. 7. Subject who has smoked within the last 6 months. 8. Subject who has alcohol or drug abuse within 12 months of screening. 9. Subject unwilling or unable to comply with study requirements.
Where it's running
-
Texas Children's Hospital
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: John Goss, M.D. — Baylor College of Medicine
- Study coordinator: Transplant Services Coordinator
- Email: uterustransplant@texaschildrens.org
- Phone: 832-822-1551
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Platelet Rich Plasma to Improve Endometrial Thickness in Infertile Women
This study is testing if using Platelet Rich Plasma can help women with thin uterine lining improve their chances of getting pregnant through IVF.
-
Deceased-donor uterine transplant for women with uterine-factor infertility
We will try a uterus transplant from a deceased donor to help women with uterine-factor infertility who can produce embryos and meet health and psychosocial requirements.
-
Uterine transplantation from living donors for women with MRKH syndrome
This study is testing if women with MRKH syndrome can successfully receive a uterus transplant from living donors to help them achieve pregnancy.
-
Uterus transplantation from a deceased donor
This study is testing if women with Mayer-Rokitansky-Küster-Hauser syndrome can become pregnant by receiving a uterus from a deceased donor and using frozen embryos.
-
Understanding the genetic causes of Mayer-Rokitansky-Kuster-Hauser syndrome
This study is trying to find out the genetic causes of Mayer-Rokitansky-Kuster-Hauser syndrome by looking at blood samples from patients and their healthy family members.
-
In vitro maturation of human eggs for fertility treatment
This study is testing a new way to help women with fertility issues by maturing their eggs in the lab with fewer hormones to see if it makes treatment easier and safer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.